Correlation between DNA damage responses of skin to a test dose of radiation and late adverse effects of earlier breast radiotherapy

Somaiah, Navita; Chua, Melvin L.K.; Bourne, S.; Daley, Frances; Hern, Roger A’; Nuta, Otilia; Gothard, Lone; Boyle, Sue; Herskind, Carsten; Pearson, Alex; Warrington, Jim; Helyer, Sarah; Owen, Roger; Rothkamm, Kai; Yarnold, John

doi:10.1016/j.radonc.2016.04.012

Cited by 11 publications

(10 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Furthermore, fibroblasts from the same patient also showed significant ex vivo radiosensitivity by γ-H2AX foci analysis [127]. More recently, ex vivo testing of lymphocytes by this technique has shown remarkable differences between groups of patients with high and low NTT grades, and/or enabled identification of patients at risk for higher grade toxicities in at least 13 publications [69,[128][129][130][131][132][133][134][135][136][137][138]. The main conclusion made in these studies was that the γ-H2AX assay may have a high potential for screening individual radiosensitivity among RT patients.…”

Section: γ-H2ax Focimentioning

confidence: 99%

Prediction of the Acute or Late Radiation Toxicity Effects in Radiotherapy Patients Using Ex Vivo Induced Biodosimetric Markers: A Review

Vinnikov

Hande

Wilkins

et al. 2020

JPM

View full text Add to dashboard Cite

A search for effective methods for the assessment of patients’ individual response to radiation is one of the important tasks of clinical radiobiology. This review summarizes available data on the use of ex vivo cytogenetic markers, typically used for biodosimetry, for the prediction of individual clinical radiosensitivity (normal tissue toxicity, NTT) in cells of cancer patients undergoing therapeutic irradiation. In approximately 50% of the relevant reports, selected for the analysis in peer-reviewed international journals, the average ex vivo induced yield of these biodosimetric markers was higher in patients with severe reactions than in patients with a lower grade of NTT. Also, a significant correlation was sometimes found between the biodosimetric marker yield and the severity of acute or late NTT reactions at an individual level, but this observation was not unequivocally proven. A similar controversy of published results was found regarding the attempts to apply G2- and γH2AX foci assays for NTT prediction. A correlation between ex vivo cytogenetic biomarker yields and NTT occurred most frequently when chromosome aberrations (not micronuclei) were measured in lymphocytes (not fibroblasts) irradiated to relatively high doses (4–6 Gy, not 2 Gy) in patients with various grades of late (not early) radiotherapy (RT) morbidity. The limitations of existing approaches are discussed, and recommendations on the improvement of the ex vivo cytogenetic testing for NTT prediction are provided. However, the efficiency of these methods still needs to be validated in properly organized clinical trials involving large and verified patient cohorts.

show abstract

Section: γ-H2ax Focimentioning

confidence: 99%

Prediction of the Acute or Late Radiation Toxicity Effects in Radiotherapy Patients Using Ex Vivo Induced Biodosimetric Markers: A Review

Vinnikov

Hande

Wilkins

et al. 2020

JPM

View full text Add to dashboard Cite

show abstract

“…Various assays for cellular radiosensitivity have been evaluated as predictive tests for late reactions, mainly using patient lymphocytes or skin fibroblasts [7], [10], [11], [12]. The approach with the best evidence for predictive value is the radiation-induced lymphocyte apoptosis (RILA) assay.…”

Section: Introductionmentioning

confidence: 99%

Multi-centre technical evaluation of the radiation-induced lymphocyte apoptosis assay as a predictive test for radiotherapy toxicity

Talbot

Veldwijk

Azria

et al. 2019

Clinical and Translational Radiation Oncology

Self Cite

View full text Add to dashboard Cite

Highlights The RILA assay is the leading candidate biomarker for radiotherapy toxicity. We describe work to standardise its use across multiple centres. Patient factors including smoking and arthritis were found to affect RILA score. RILA predicts acute breast pain but not other acute end-points. This work establishes the basis for implementing the assay clinically.

show abstract

“…Those latter patients displayed a delay in nucleoshuttling of the ATM protein in response to ionizing radiation of normal tissue. To date, no prospective study showed that one of those assays was able to predict severe late toxicities occurrence ( 26 , 27 ).…”

Section: Radio-induced Toxicity Biomarkers Eramentioning

confidence: 99%

Personalizing Breast Cancer Irradiation Using Biology: From Bench to the Accelerator

et al. 2018

View full text Add to dashboard Cite

While adjuvant treatments of early breast cancers (BCs) had significantly improved patients’ overall survival, some of them will still develop locoregional relapses and/or severe late radio-induced toxicities. Here, we propose to review how to personalize locoregional treatment by identifying patients at high and low risk of locoregional relapse, patients at risk of late radio-induced side effects. We will, therefore, discuss how to enhance BC radiosensitivity. Finally, we will address how personalized radiotherapy could be implemented in prospective clinical trials.

show abstract

Correlation between DNA damage responses of skin to a test dose of radiation and late adverse effects of earlier breast radiotherapy

Cited by 11 publications

References 22 publications

Prediction of the Acute or Late Radiation Toxicity Effects in Radiotherapy Patients Using Ex Vivo Induced Biodosimetric Markers: A Review

Prediction of the Acute or Late Radiation Toxicity Effects in Radiotherapy Patients Using Ex Vivo Induced Biodosimetric Markers: A Review

Multi-centre technical evaluation of the radiation-induced lymphocyte apoptosis assay as a predictive test for radiotherapy toxicity

Personalizing Breast Cancer Irradiation Using Biology: From Bench to the Accelerator

Contact Info

Product

Resources

About